Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, or transcatheter aortic valve replacement, growth slowed post-COVID, but added that the upgrade is predicated on “now more credible TAVR growth re-acceleration potential” following six recent TAVR physician conversations and a subsequent survey of thirty physicians. Stifel noted that fifteen of the thirty doctors surveyed said they are “already experiencing faster TAVR procedure growth,” with those fifteen doctors noting “~12% near-term growth acceleration.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences upgraded to Buy from Hold at Stifel
- Edwards Lifesciences call volume above normal and directionally bullish
- Buy/Sell: Wall Street’s top 10 stock calls this week
- UnitedHealth, BofA report Q4 earnings beats: Morning Buzz
- Edwards Lifesciences downgraded to Underperform at Wolfe Research